OS Therapies Inc (NYSE-A:OSTX) shares jumped 12.4% following favorable feedback from the FDA regarding its OST-HER2 treatment ...

"The favorable safety profile of OST-HER2 compared with standard of care is also an important quality of life factor when assessing potential new treatment options for this difficult to treat patient ...

No patients discontinued gedatolisib due to a treatment-related AE. One (2.3%) patient experienced Grade 3 hyperglycemia. “The 43% ORR reported in patients who received at least three prior lines of ...

"With the advent of anti-HER2 therapy in metastatic colorectal cancer, the key question for HER2-amplified RAS/BRAF wild-type tumors is who should be preferentially treated with therapy directed ...

June brought major breast cancer updates, and CURE is sharing the latest treatment combinations, biomarker-driven care and ...

In a large Chinese trial presented at the American Society of Clinical Oncology annual meeting, neoadjuvant therapy with a ...

Anti-HER2 therapies: treatments that target and block the HER2 protein, which can promote the growth of cancer cells, often used in breast cancer treatment. Circulating tumor DNA: small fragments of ...

A phase 2 trial finds that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy.

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.

In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a ...

The most common treatment for HER2-positive breast cancer is chemotherapy plus HER2-directed therapy. This is followed by surgery, then continues with HER2-directed therapy.